New hope for kids with Drug-Resistant TB: delamanid studied in children
NCT ID NCT03141060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug delamanid in 37 children with multidrug-resistant tuberculosis (MDR-TB), some of whom also had HIV. The goal was to see how the drug works in the body, check for side effects, and find the right dose. Children took delamanid along with their regular TB medicines for 24 weeks. The results help doctors understand how to safely use this treatment in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
delamanid
What this could lead to
If successful, this could help establish safe and effective dosing of delamanid for children with drug-resistant TB, improving treatment options for this hard-to-treat infection.
What could go wrong
This was a small, early-phase study (37 children) focused on safety and drug levels, not on cure rates. Side effects like heart rhythm changes or severe adverse events are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIDRUG-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, 411001, India
-
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, 7505, South Africa
-
Kilimanjaro Christian Medical Centre (KCMC)
Moshi, Tanzania
-
PHRU Matlosana CRS
Klerksdorp, North West, 2574, South Africa
-
Sizwe CRS
Johannesburg, Gauteng, South Africa